Synta Provides Clinical Update and Reports Second Quarter 2012 Financial Results

by Blog Burger on August 2, 2012

LEXINGTON, Mass.–(BUSINESS WIRE)–Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today reported financial results for the quarter ended June 30, 2012 and provided clinical program updates. “We are excited by the potential benefit ganetespib may bring to patients” “We continue to make strong progress in advancing our ganetespib program along two parallel paths to registration: as a monotherapy in certain targeted cancer patient populations, and in combination with chemotherapy in a broader patient population,” said Safi Bahcall, Ph.D., President and CEO. “We expect important clinical results over the next 12 months from trials evaluating both approaches, including interim results… – Health News

Comments on this entry are closed.

Previous post:

Next post: